NBI

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Martedì, Marzo 19, 2024
Research, Moyamoya disease, Quarter, Cardiovascular disease, Spirited, Growth, Exercise, Entrepreneurship, IL-6, Inflammation, Patient, SVP, Business development, Commercial, NASDAQ Biotechnology Index, MD, IND, Investment, Clinical trial, NBI, Investigational New Drug, Therapy, TRML, Medical research, Graves' ophthalmopathy, FDA, Food, Pharmaceutical industry

In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.

Key Points: 
  • In October 2023, Tourmaline become a publicly-traded company via reverse merger with Talaris Therapeutics, including a concurrent private placement of $75.0 million.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash, cash equivalents and investments were $203.0 million as of December 31, 2023, as compared to $8.3 million as of December 31, 2022.
  • Research and development expenses were $8.0 million for the fourth quarter of 2023, as compared to $3.8 million for the fourth quarter of 2022.
  • General and administrative expenses were $6.9 million for the fourth quarter of 2023, as compared to $1.1 million for the fourth quarter of 2022.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Mercoledì, Marzo 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

Quantum Experts Join Forces to Revolutionize European Quantum Computing

Retrieved on: 
Giovedì, Marzo 14, 2024
Science, Software, Nanotechnology, Research, Hardware, Data Management, Technology, Semiconductor, Noise, Partnership, Acquisition, NBI, Niels Bohr Institute, Machine learning, Multimedia, SME, Microscope

This landmark initiative brings together quantum experts from the United Kingdom, Germany, and Denmark with a shared goal of accelerating the development and commercialization of photonic quantum computing technologies to deliver quantum advantage.

Key Points: 
  • This landmark initiative brings together quantum experts from the United Kingdom, Germany, and Denmark with a shared goal of accelerating the development and commercialization of photonic quantum computing technologies to deliver quantum advantage.
  • It will draw upon single-photon sources from Sparrow Quantum and NBI, single-photon detectors from Pixel Photonics, and full-stack photonic quantum computing system architecture from ORCA Computing.
  • By uniting efforts, the SupremeQ consortium aims to drive breakthrough innovation in photonic quantum computing, paving the way for quantum advantage.
  • These advancements are necessary for the commercialization of quantum computers to reach advantage over classical computing systems signifying a significant leap toward achieving universal fault-tolerant quantum computing.

National Bank Investments Inc. and Evovest Inc. Launch the Evovest Global Equity ETF

Retrieved on: 
Giovedì, Marzo 28, 2024
Toronto Stock Exchange, TSX, NBI, ETF

MONTREAL, March 28, 2024 /CNW/ - National Bank Investments Inc. ("NBI" or the "Investment Fund Manager") and Evovest Inc. ("Evovest" or the "Portfolio Manager") (together, the "Promoters") announced today the launch of the Evovest Global Equity ETF (the "ETF").

Key Points: 
  • MONTREAL, March 28, 2024 /CNW/ - National Bank Investments Inc. ("NBI" or the "Investment Fund Manager") and Evovest Inc. ("Evovest" or the "Portfolio Manager") (together, the "Promoters") announced today the launch of the Evovest Global Equity ETF (the "ETF").
  • The ETF has closed the initial offering of units, and those units will start trading on the Toronto Stock Exchange ("TSX") today.
  • "We are proud to announce the launch of the Evovest Global Equity ETF with National Bank Investments, a significant milestone that reflects our continued evolution and team efforts.
  • NBI will act as Investment Fund Manager of the ETF and Evovest will act as Portfolio Manager of the ETF.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercoledì, Marzo 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Giovedì, Febbraio 29, 2024
Acquisition, Research, Reiterate, Neoplasm, FDA, Cancer, Adium, Disassembler, International Society, NASDAQ Biotechnology Index, Interim, GM-CSF, Self-assembly, NBI, Therapy, Interest, Patient, HITS, Clinical trial, Congress, IND, Human, Cryptocurrency

On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.

Key Points: 
  • On October 18, 2023, Y-mAbs announced that its Board of Directors appointed radiopharmaceutical industry veteran Mr. Rossi as President and Chief Executive Officer, effective November 6, 2023.
  • The DANYELZA net product revenues of $23.4 million in the fourth quarter of 2023, represented a favorable 17% increase compared to the third quarter of 2023, primarily driven by increased U.S. sales.
  • The Company did not have license revenues in the quarter ended December 31, 2023 and had license revenues of $0.5 million for the year ended December 31, 2023.
  • The net income for the quarter ended December 31, 2022, was after $15.0 million of license revenue recognized in the fourth quarter of 2022.

Strategic Imperatives and X3T announce merger to accelerate connections between AltNets and ISPs

Retrieved on: 
Martedì, Gennaio 23, 2024
Openreach, Internet service provider, Knowledge, Sabbagh, Software as a service, Tetrad, McCourt, NBI, Internet

Founded in 2006, Strategic Imperatives quickly established itself as the principal provider of fixed line solutions into the Openreach network, provisioning, ceasing and migrating millions of connections.

Key Points: 
  • Founded in 2006, Strategic Imperatives quickly established itself as the principal provider of fixed line solutions into the Openreach network, provisioning, ceasing and migrating millions of connections.
  • "This merger with Strategic Imperatives means we can share this knowledge and accelerate our support for customers in the UK and beyond.
  • As an investor, owner and operator, we know first-hand that the combined capabilities of X3T and Strategic Imperatives provides the blueprint for AltNets and ISPs to scale," concluded McCourt.
  • The merger was supported by Clarkslegal acting for X3T and Russell-Cooke on behalf of Strategic Imperatives.

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

Retrieved on: 
Giovedì, Gennaio 4, 2024
HER2, Biotechnology, Autoimmunity, FDA, Spacecraft, GEA, File, Publishing, Inflammation, Society, Cancer, Russell 3000 Index, Conference, IND, BTC, Prevalence, Jazz Pharmaceuticals, GPC3, Webcast, Patient, Senior, Environment, NASDAQ Biotechnology Index, BeiGene, Trial of the century, Standard of care, FIH, Publication, ADC, NBI, BLA, Pharmaceutical industry

Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.

Key Points: 
  • Beyond ZW191, we are planning additional IND filings and FIH studies for ZW220 (NaPi2b) and ZW251 (GPC3) to commence in 2025.
  • “Our strong financial position allows us to be opportunistic in evaluating additional R&D opportunities and pursuing potential strategic partnerships and collaborations.
  • We expect to submit INDs for ZW171 and ZW191 in 2024, and INDs for ZW220 and ZW251 in 2025.
  • An R&D Day to highlight our progress and future R&D strategy will be held in the fourth quarter of 2024.

Zymeworks Added to Nasdaq Biotechnology Index

Retrieved on: 
Venerdì, Dicembre 15, 2023
Industry Classification Benchmark, NASDAQ Biotechnology Index, NBI, Biotechnology

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”).
  • Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023.
  • The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark.
  • The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.

Tourmaline Bio added to the NASDAQ Biotechnology Index

Retrieved on: 
Venerdì, Dicembre 15, 2023
Industry Classification Benchmark, NASDAQ Biotechnology Index, TRML, Patient, Inflammation, NBI, Biotechnology, Fine chemical

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Tourmaline has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 18, 2023.

Key Points: 
  • NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Tourmaline has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open, Monday, December 18, 2023.
  • The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.
  • The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
  • Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria.